Kim Raineri, Chief Technology Officer of Aspen Neuroscience, Inc. (NASDAQ:ASPE), filed an initial statement of beneficial ownership on October 29, 2026, disclosing three stock option grants covering a total of 182,146 shares of common stock.

Key Highlights

  • Reporting person: Kim Raineri, identified as Chief Technology Officer of Aspen Neuroscience, Inc.
  • First option: 70,835 shares of common stock, exercise price $7.71, expiration September 6, 2032, fully vested and exercisable, granted September 7, 2022.
  • Second option: 30,357 shares of common stock, exercise price $7.42, expiration September 26, 2033, granted September 27, 2023, with 1/4th vested on October 1, 2024 and 1/48th vesting monthly thereafter.
  • Third option: 80,954 shares of common stock, exercise price $5.74, expiration November 25, 2035, granted November 26, 2025, vesting at 1/48th per month beginning December 20, 2025.
  • No non-derivative securities: Table I of the filing reports no directly or indirectly held non-derivative securities.
  • All holdings direct: All three options are held directly by the reporting person.

Aspen Neuroscience CTO Raineri Discloses Three Stock Option Grants at Varying Exercise Prices

According to the Form 3 filing submitted to the SEC on October 29, 2026, Kim Raineri reported initial beneficial ownership of securities in Aspen Neuroscience, Inc. (NASDAQ:ASPE) upon becoming subject to Section 16(a) reporting obligations as the company's Chief Technology Officer. The filing lists no non-derivative securities held directly or indirectly, but discloses three separate stock option grants in Table II.

The first option, the filing states, covers 70,835 shares of common stock at an exercise price of $7.71 per share, with an expiration date of September 6, 2032. According to the filing's explanation of responses, this option was granted on September 7, 2022, and "is fully vested and exercisable." The second option covers 30,357 shares at an exercise price of $7.42 per share, expiring September 26, 2033. The filing notes it was granted on September 27, 2023, with 1/4th having vested on October 1, 2024, and 1/48th vesting on the same day of each month thereafter, subject to continued service through each vesting date.

The third option covers 80,954 shares at an exercise price of $5.74 per share, expiring November 25, 2035. Per the filing, this option was granted on November 26, 2025, with vesting occurring at 1/48th per month beginning December 20, 2025, also subject to continued service through each vesting date. All three options are held directly and represent rights to purchase shares of Aspen Neuroscience common stock. The filing was signed by Jeffrey L. Boerneke as Attorney-in-Fact under an attached Power of Attorney.

What Was Disclosed

Kim Raineri, Chief Technology Officer of Aspen Neuroscience, Inc., filed an initial beneficial ownership report disclosing three stock options covering 182,146 total shares of common stock, with exercise prices ranging from $5.74 to $7.71 and varying vesting schedules.